Consumer Business Keeps J&J Fresh In Challenging Quarter
This article was originally published in The Rose Sheet
Executive Summary
Johnson & Johnson's second quarter results show the firm's move toward broader diversification with the purchase of Pfizer's consumer business was a shrewd one, as personal care and over-the-counter countered weak performance in the pharma sector